Latest Insider Transactions at Schrodinger, Inc. (SDGR)
This section provides a real-time view of insider transactions for Schrodinger, Inc. (SDGR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Schrodinger, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Schrodinger, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 15
2024
|
Margaret Dugan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,531
-10.21%
|
$26,027
$17.78 P/Share
|
|
Jun 18
2024
|
Arun Oberoi Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Michael Lynton Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Rosana Kapeller Libermann Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Jeffrey Chodakewitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Gary L Ginsberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Richard Friesner Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+0.96%
|
-
|
|
Jun 18
2024
|
Nancy Thornberry Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Gary Sender Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Mar 06
2024
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
BUY
Exercise of conversion of derivative security
|
Direct |
5,574
+11.7%
|
$22,296
$4.34 P/Share
|
|
Mar 04
2024
|
Geoffrey Craig Porges EVP & CFO |
SELL
Open market or private sale
|
Direct |
3,315
-36.83%
|
$86,190
$26.35 P/Share
|
|
Mar 04
2024
|
Geoffrey Craig Porges EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
Mar 04
2024
|
Jenny Herman SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
7,313
+27.71%
|
-
|
|
Feb 12
2024
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
SELL
Open market or private sale
|
Direct |
901
-2.41%
|
$25,228
$28.29 P/Share
|
|
Feb 12
2024
|
Jenny Herman SVP & Controller |
SELL
Open market or private sale
|
Direct |
787
-6.27%
|
$22,036
$28.29 P/Share
|
|
Feb 12
2024
|
Robert Lorne Abel Officer |
SELL
Open market or private sale
|
Direct |
1,205
-11.43%
|
$32,535
$27.55 P/Share
|
|
Feb 12
2024
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
758
-5.96%
|
$21,224
$28.29 P/Share
|
|
Sep 15
2023
|
Jenny Herman SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
4,545
+26.59%
|
$4,545
$1.2 P/Share
|
|
Aug 09
2023
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
SELL
Open market or private sale
|
Direct |
10,000
-21.1%
|
$400,000
$40.06 P/Share
|
|
Aug 09
2023
|
Margaret Dugan Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Jun 30
2023
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
12,040
-48.62%
|
$602,000
$50.0 P/Share
|
|
Jun 30
2023
|
Yvonne Tran EVP, CLO & CPO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,040
+32.72%
|
$204,680
$17.0 P/Share
|
|
Jun 15
2023
|
Rosana Kapeller Libermann Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Jeffrey Chodakewitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Nancy Thornberry Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Michael Lynton Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Arun Oberoi Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Gary Sender Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 15
2023
|
Richard Friesner Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+1.21%
|
-
|
|
Jun 15
2023
|
Gary L Ginsberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
May 23
2023
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
SELL
Open market or private sale
|
Direct |
10,000
-17.43%
|
$400,000
$40.06 P/Share
|
|
May 23
2023
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
7,960
-38.49%
|
$318,400
$40.01 P/Share
|
|
May 23
2023
|
Yvonne Tran EVP, CLO & CPO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,960
+27.79%
|
$31,840
$4.34 P/Share
|
|
May 22
2023
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
15,000
-54.11%
|
$525,000
$35.04 P/Share
|
|
May 22
2023
|
Yvonne Tran EVP, CLO & CPO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+17.89%
|
$45,000
$3.71 P/Share
|
|
May 22
2023
|
Nancy Thornberry Director |
SELL
Open market or private sale
|
Direct |
14,850
-100.0%
|
$519,750
$35.0 P/Share
|
|
May 22
2023
|
Nancy Thornberry Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,850
+50.0%
|
$163,350
$11.52 P/Share
|
|
Feb 09
2023
|
Jenny Herman SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+49.99%
|
-
|
|
Feb 09
2023
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
BUY
Grant, award, or other acquisition
|
Direct |
8,170
+12.46%
|
-
|
|
Feb 09
2023
|
Yvonne Tran EVP, CLO & CPO |
BUY
Grant, award, or other acquisition
|
Direct |
7,590
+37.37%
|
-
|
|
Feb 09
2023
|
Robert Lorne Abel Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,545
+50.0%
|
-
|
|
Feb 02
2023
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
25,000
-82.97%
|
$675,000
$27.26 P/Share
|
|
Feb 02
2023
|
Yvonne Tran EVP, CLO & CPO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+35.8%
|
$50,000
$3.0 P/Share
|
|
Jan 04
2023
|
Ramy Farid President & CEO |
SELL
Open market or private sale
|
Direct |
66,886
-26.61%
|
$1,203,948
$18.28 P/Share
|
|
Jan 04
2023
|
Ramy Farid President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
66,886
+21.02%
|
$66,886
$1.2 P/Share
|
|
Aug 11
2022
|
Nancy Thornberry Director |
SELL
Open market or private sale
|
Direct |
4,950
-100.0%
|
$173,250
$35.0 P/Share
|
|
Aug 11
2022
|
Nancy Thornberry Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,950
+50.0%
|
$54,450
$11.52 P/Share
|
|
Dec 13
2021
|
Robert Lorne Abel Officer |
SELL
Open market or private sale
|
Direct |
15,601
-93.91%
|
$561,636
$36.54 P/Share
|
|
Dec 13
2021
|
Robert Lorne Abel Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,601
+50.0%
|
$265,217
$17.0 P/Share
|
|
Oct 15
2021
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
1,393
-100.0%
|
$76,615
$55.75 P/Share
|